Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Oncologist. 2023 Jan 18;28(1):e77-e81. doi: 10.1093/oncolo/oyac234.

Abstract

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).

Keywords: CDK4/6; Ki-67; abemaciclib; adjuvant; early breast cancer.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzimidazoles / therapeutic use
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor, ErbB-2* / therapeutic use

Substances

  • abemaciclib
  • Aminopyridines
  • Benzimidazoles
  • Protein Kinase Inhibitors
  • Receptor, ErbB-2

Associated data

  • ClinicalTrials.gov/NCT03155997